New drug cocktail aims to stop aggressive liver cancer from coming back
NCT ID NCT04669496
First seen Oct 31, 2025 · Last updated Apr 18, 2026 · Updated 20 times
Summary
This study is testing a combination of three drugs (an immunotherapy, a targeted therapy, and chemotherapy) given before surgery for a type of bile duct cancer in the liver. The goal is to shrink tumors and lower the high risk of the cancer returning after surgery. Researchers will compare this new approach to the current standard of going straight to surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan hospital
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.